Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401765 · ClinicalTrials.gov registry record · Phase 1
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00401765 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 40 participants.
The verdict
NCT00401765, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate cancer.
Interventions
- DRUG Docetaxel
- DRUG CNTO 328
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401765
The ClinicalTrials.gov registry entry for NCT00401765 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00401765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401765 about?
NCT00401765 is a clinical study titled "A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer". The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate cancer.
What is the current status of trial NCT00401765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00401765?
The interventions under investigation include: Docetaxel (DRUG), CNTO 328 (DRUG).
Who is sponsoring clinical trial NCT00401765?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.